CoChat

Bone Mineral Density After Transitioning From Denosumab to Alendronate

Open access
Kendler, David, Chines, Arkadi, Clark, Patricia, Ebeling, Peter R, McClung, Michael, Rhee, Yumie, Huang, Shuang, Stad, Robert Kees · 2020 · The Journal of Clinical Endocrinology & Metabolism
Cited by 119

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Context: There are few studies on patients transitioning from denosumab to bisphosphonates. Objective: To investigate patient characteristics and changes in bone mineral density (BMD) after transitioning from denosumab to alendronate. Design: Randomized, open-label, 2-year crossover Denosumab Adherence Preference Satisfaction (DAPS) study (NCT00518531). Setting: 25 study centers in the US and Canada. Patients: Treatment-naïve postmenopausal women with BMD T-scores from −2.0 to −4.0. Interventions: This post hoc analysis evaluated women randomized to subcutaneous denosumab 60 mg every 6 months in year 1 followed by once-weekly oral alendronate 70 mg in year 2. Main Outcome Measure: A 3% BMD threshold identified participants who lost, maintained, or gained BMD in year 2 on alendronate. Results: Of 126 participants randomized to denosumab, 115 (91%) transitioned to alendronate in year 2. BMD increased by 3% to 6% with denosumab in year 1 and by 0% to 1% with alendronate in year 2. After transitioning to alendronate, most participants maintained or increased BMD; 15.9%, 7.6%, and 21.7% lost BMD at the lumbar spine, total hip, and femoral neck, respectively. Few participants fell below their pretreatment baseline BMD value; this occurred most often in those who lost BMD in year 2. Women who lost BMD with alendronate in year 2 also showed a greater percent change in BMD with denosumab in year 1. The BMD change in year 2 was similar regardless of baseline characteristics or adherence to oral alendronate. Conclusion: Alendronate can effectively maintain the BMD gains accrued after 1 year of denosumab in most patients, regardless of baseline characteristics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgz095

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 119

Metadata

Authors
Kendler, D., Chines, A., Clark, P., Ebeling, P. R., McClung, M., Rhee, Y., Huang, S., & Stad, R. K.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2019-10-26
Volume
105
Issue
3
Pages
e255-e264
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2982598109
Cited by
119
References
7
FWCI
13.27
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bone Mineral Density After Transitioning From Denosumab to Alendronate. https://app.cochat.ai/papers/10.1210/clinem/dgz095
The paper
Kendler, D., Chines, A., Clark, P., Ebeling, P. R., McClung, M., Rhee, Y., Huang, S., & Stad, R. K. (2020). Bone Mineral Density After Transitioning From Denosumab to Alendronate. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgz095

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.